UCM-1306

UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD). In Vitro UCM-1306 (2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl; 1-10 μM) increases cAMP in a concentration-response manner with high potency (EC 50 =60 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo UCM-1306 (2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl; 5 mg/kg; p.o.; C57BL/6J mice) has good brain penetration and oral availability. Plasma concentration can be quantified for up to 8 h with T max at 0.5 h . UCM-1306 (1 mg/kg; ip) enhances cocaine-induced hyperlocomotion in adult mice . UCM-1306 (1 mg/kg; ip) helps consolidate long-term memory formation . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult C57BL/6J mice with cocaine-induced hyperactivity model Dosage: 1 mg/kg; cocaine (20 mg/kg, sc) Administration: Intraperitoneal injection Result: Increased cocaine-induced hyperlocomotion, suggesting an in vivo potentiation of DA action at the D1R. Animal Model: Adult C57BL/6J mice Dosage: 1 mg/kg Administration: Intraperitoneal injection Result: Increased memory trace in C57BL/6J mice. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet